Brought to you by 
Immunocore gets its third major partner, through new ImmTAC deal with MedImmune
03 Mar 2023
Executive Summary
Immunocore Ltd. (develops bi-functional proteins) will work with AstraZeneca PLC’s MedImmune LLC to develop new cancer candidates based on Immunocore’s Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) platform.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immunocore gets its third major partner, through new ImmTAC deal with MedImmune
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice